Skip to main content

Table 1 Characteristics of the patients enrolled in the study

From: Predictive impact of polymorphism of PNPLA3 on HCC development after interferon therapy in Japanese patients with chronic hepatitis C

Patient characteristics

N = 271

Age (years)

57 ± 10

Sex (male/female)

140/131

Body mass index

24 ± 3

Liver fibrosis (Stage 1/2/3/4)

71/82/60/6

Hepatitis activity (Grade 1/2/3)

164/49/6

rs 8099917 of IL28B (TT/TG/GG)

198/72/1

rs 738409 of PNPLA3 (CC/CG/GG)

81/136/54

HCV core amino acids 70 (arginine/glutamine)

150/91

Alanine aminotransferase (IU/L)

66 ± 55

Platelet count (10000 /mm3)

17 ± 6

Alpha fetoprotein (ng/mL)

11 ± 19

HOMA-IR

4.2 ± 8.4

Therapeutic outcome (SVR/relapse/NVR)

126/77/68

  1. : Mean ± standard deviation; PNPLA3, patatin-like phospholipase domain-containing protein 3; HOMA-IR, homeostasis model assessment insulin resistance; SVR, sustained virological response; NVR, null or partial virological response.